Abstract
Objective: To assess prospectively the safety and efficacy of a 36-month course of systematic bolus intravenous cyclophosphamide therapy (IVCY) for children with lupus nephritis. Study design: Sixteen children with lupus nephritis were treated with IVCY for 36 months. Renal biopsies performed before and after treatment were scored for activity and chronicity. SLEDAI scores, laboratory measures, and prednisone dosage were recorded at the time of each treatment. Results: After 36 months of IVCY therapy, the renal biopsy activity index decreased from 9 ± 4 to 1 ± 1 ( P < .001) without a change in chronicity. The mean creatinine clearance increased from 90 ± 23 to 107 ± 23 mL/min/1.73 mol/L 2 ( P < .01), and the mean 24-hour urine protein excretion decreased from 2.0 ± 2.4 g/24 h to 0.5 ± 0.7 g/24 h ( P < .05). The mean SLEDAI score decreased from 19 ± 5.2 to 2.9 ± 3.1 ( P < .001). The mean prednisone dosage decreased from 35.5 ± 20 mg/d to 14.0 ± 3 mg/d ( P < .001). No significant complications occurred. Conclusions: Thirty-six months of systematic IVCY therapy led to decreased renal biopsy activity without progression of chronicity, with excellent disease control and a greater than 50% reduction in mean corticosteroid dose. (J Pediatr 2000;136:243-7)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
